Clinical Trials
3 trialsNCT06022757 2024-02-23
KEYNOTE F19
Evopoint Biosciences Inc.
Phase 1/2 Recruiting
NCT01976741 2021-05-06
Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)
Bayer
Phase 1 Completed
NCT00210080 2015-09-04
A Study to Diagnose Lung Cancer by Sputum Cytology (01-312)
Merck Sharp & Dohme LLC
Phase 3 Completed